A consortium led by the Royal College of Surgeons in Ireland (RCSI) and the new Science Foundation Ireland centre Amber has received €8.7m funding for research into heart disease.
Called Amcare (Advanced Materials for Cardiac Regeneraton), the group involves ten partners from five European countries and the funding is part of the EU’s Framework Programme 7.
The Amcare programme, which will create ten new positions, will carry out research to develop natural materials and new surgical devices to enhance the delivery of the body’s own stem cells to the heart to promote healing after a heart attack and prevent premature death.
The therapies being developed will replace heart cells that die due to the reduced blood flow that occurs during a heart attack, with new healthy cells derived from stem cells that come from the patient’s own bone marrow.
Amcare is co-ordinated by Dr Garry Duffy, Department of Anatomy and Tissue Engineering Research Group, RCSI and Amber investigator.
He said: “Regenerative medicine and stem cell therapies have the potential to revolutionise the treatment of patients who have suffered a heart attack, and through Amcare we will develop new technologies to enhance stem cell therapies for these patients by increasing targeting and ease of delivery using advanced biomaterials.”